New hope for Tough-to-Treat lung cancer when standard therapy fails
NCT ID NCT05020457
Summary
This study is testing whether adding an experimental drug called SI-B001 to standard chemotherapy can help control advanced non-small cell lung cancer that has worsened despite prior immunotherapy. It involves about 69 adults whose cancer has specific genetic markers (EGFR and ALK wild-type) and has spread or returned. The main goals are to see if the combination is safe and if it shrinks tumors or slows their growth.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Chongqing University Cancer Hospital
Chongqing, Chongqing Municipality, China
-
Shandong Cancer Hospital
Jinan, Shandong, China
-
Sun Yat-sen University Cancer Center (SYSUCC)
Guangzhou, Guangdong, 510075, China
-
TaiZhou Hospital of Zhejiang Province
Taizhou, Zhejiang, China
-
The Second Affiliated Hospital of Guangzhou Medical University
Guangzhou, Guangdong, China
-
The Second Affiliated Hospital of Guilin Medical University
Guilin, Guangxi, China
Conditions
Explore the condition pages connected to this study.